Oklahoma Cancer Specialists and Research Institute, LLC

Tulsa, Oklahoma 74146

3 studies enrolling now · 19 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Cervical Cancer, Endometrial Cancer, Endometrial Carcinoma, Endometroid Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) — Recruiting now
• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer — Recruiting now
• A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer — Recruiting now
• A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer — Running, not enrolling
• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation — Stopped early
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Running, not enrolling
• RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer — Stopped early
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer — Completed
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
• Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• A Trial of Tisotumab Vedotin in Cervical Cancer — Completed
• An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer — Stopped early
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer — Completed
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC — Stopped early
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer — Completed
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer — Completed
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed